Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 06, 2022 07:30 ET | Source: Biogen Inc.

Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease

AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease modifying treatment for Parkinson’s DiseaseAlectos to receive a $15 million upfront payment and is...
June 03, 2022 08:00 ET | Source: Biogen Inc.

Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)

CAMBRIDGE, Mass. and GUANGZHOU, China, June 03, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today presented positive Phase 3 data for BIIB800...
June 03, 2022 05:20 ET | Source: Biogen Inc.

New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benefit in People With SOD1-ALS

12-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength, and quality of lifeTofersen also led to robust and sustained...
May 05, 2022 07:30 ET | Source: Biogen Inc.

Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis

The investigational prescription digital therapeutic uses a combination of sensors, software, and music based on Rhythmic Auditory Stimulation (RAS)MedRhythms to receive a $3 million upfront payment...
April 04, 2022 16:06 ET | Source: Biogen Inc.

New Data at AAN 2022 Highlight Real-World Evidence from Biogen’s MS Portfolio and Emerging Research on Disease Progression

Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every four-week dosingAdditional real-world data affirm...
March 30, 2022 07:30 ET | Source: Biogen Inc.

Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA

Confirmatory trial’s completion is expected in an accelerated timeline of four years with patient screening to start in MayMultiple strategies in place to enroll patients that are representative of...
March 28, 2022 07:30 ET | Source: Biogen Inc.

Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis

BIIB078, an investigational antisense oligonucleotide for C9orf72-associated amyotrophic lateral sclerosis (ALS), did not show clinical benefit; clinical program will be discontinuedBiogen and Ionis...
March 16, 2022 11:54 ET | Source: Biogen Inc.

Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease

CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that The Journal of Prevention of Alzheimer’s Disease (JPAD) today published a peer-reviewed manuscript...
March 16, 2022 07:30 ET | Source: Biogen Inc.

Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years

ADUHELM continued to reduce two key Alzheimer’s disease pathologies, amyloid beta plaques and p-tau181, in patients treated for up to two and a half yearsData from both Phase 3 studies also show that...
March 14, 2022 19:00 ET | Source: Biogen Inc.

Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments

Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023Lecanemab collaboration to continue unchanged...